Griffin Stephen D.
Griffin Stephen D.'s purchase track record
Griffin Stephen D. has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/30/2026 | ANIK | $150K | +45.1% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
VSEC Reports Q2 2026 Results and Cited as Volatile Stock. VSE Corporation held its Q2 2026 earnings call, providing an update on its recent performance. In a separate market commentary, VSEC was listed among stocks noted for high volatility and risk. The earnings discussion and the volatility focus both draw attention to the company's current market dynamics.
Transaction History
| ANIK | ▲ Buy | Option Exercise | 12,840 | — | 6/3/2026 | View on chart |
| ANIK | ▼ Sell | Tax Withholding | 3,769 | $54K | 6/3/2026 | View on chart |
| ANIK | ▲ Buy | Open Market | 12,200 | $150K | 4/30/2026 | View on chart |
| ANIK | ▲ Buy | Option Exercise | 12,824 | — | 3/14/2026 | View on chart |
| ANIK | ▲ Buy | Grant | 6,412 | $0 | 3/14/2026 | View on chart |
| ANIK | ▼ Sell | Tax Withholding | 5,944 | $84K | 3/14/2026 | View on chart |
| ANIK | ▲ Buy | Option Exercise | 12,840 | $0 | 6/3/2025 | View on chart |
| ANIK | ▼ Sell | Tax Withholding | 3,769 | $44K | 6/3/2025 | View on chart |
| VSEC | ▼ Sell | Tax Withholding | 1,160 | $92K | 4/1/2024 | View on chart |
| VSEC | ▲ Buy | Grant | 2,567 | $0 | 3/31/2024 | View on chart |
| VSEC | ▲ Buy | Option Exercise | 1,287 | $0 | 3/31/2024 | View on chart |
| VSEC | ▲ Buy | Option Exercise | 1,324 | — | 3/11/2024 | View on chart |
| VSEC | ▼ Sell | Tax Withholding | 3,031 | $228K | 3/11/2024 | View on chart |
| VSEC | ▲ Buy | Grant | 1,821 | $0 | 3/11/2024 | View on chart |
| VSEC | ▲ Buy | Option Exercise | 1,832 | — | 3/10/2024 | View on chart |
| VSEC | ▲ Buy | Grant | 5,132 | $0 | 3/10/2024 | View on chart |
| VSEC | ▲ Buy | Grant | 233 | $11K | 12/29/2023 | View on chart |
| VSEC | ▲ Buy | Grant | 268 | $11K | 6/30/2023 | View on chart |
| VSEC | ▼ Sell | Tax Withholding | 814 | $37K | 3/31/2023 | View on chart |
| VSEC | ▲ Buy | Option Exercise | 1,288 | $0 | 3/31/2023 | View on chart |
| VSEC | ▲ Buy | Grant | 1,416 | $0 | 3/31/2023 | View on chart |
| VSEC | ▼ Sell | Tax Withholding | 947 | $39K | 3/13/2023 | View on chart |
| VSEC | ▲ Buy | Option Exercise | 1,324 | $0 | 3/11/2023 | View on chart |
| VSEC | ▲ Buy | Grant | 1,820 | $0 | 3/11/2023 | View on chart |
| VSEC | ▼ Sell | Tax Withholding | 20 | $845 | 3/10/2023 | View on chart |
| VSEC | ▲ Buy | Grant | 66 | $0 | 3/10/2023 | View on chart |
| VSEC | ▲ Buy | Grant | 141 | $5K | 12/30/2022 | View on chart |
| VSEC | ▼ Sell | Tax Withholding | 1,506 | $73K | 11/9/2022 | View on chart |
| VSEC | ▲ Buy | Grant | 5,000 | $0 | 11/9/2022 | View on chart |
| VSEC | ▲ Buy | Grant | 323 | $11K | 6/30/2022 | View on chart |
| VSEC | ▲ Buy | Option Exercise | 1,288 | $0 | 3/31/2022 | View on chart |
| VSEC | ▼ Sell | Tax Withholding | 777 | $36K | 3/31/2022 | View on chart |
| VSEC | ▲ Buy | Grant | 1,328 | $0 | 3/31/2022 | View on chart |
| VSEC | ▲ Buy | Grant | 64 | $0 | 3/11/2022 | View on chart |
| VSEC | ▼ Sell | Tax Withholding | 19 | $823 | 3/11/2022 | View on chart |
| VSEC | ▲ Buy | Grant | 204 | $9K | 12/31/2021 | View on chart |
| VSEC | ▲ Buy | Grant | 5,000 | $0 | 11/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ANIK Stock Moves Amid Broader Biotech Sector News
Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.
ANIK Stock Moves Amid Broader Biotech Sector News. Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.